Coherus Oncology (CHRS) Notes Payables (2013 - 2025)

Coherus Oncology (CHRS) has 11 years of Notes Payables data on file, last reported at $26.2 million in Q1 2025.

• For the quarter ending Q1 2025, Notes Payables changed N/A year-over-year to $26.2 million; the trailing twelve-month figure through Mar 2025 stood at $26.2 million (changed N/A YoY), and the FY2024 full-year result was $13.6 million, changed N/A from the prior year.
• Notes Payables climbed to $26.2 million in Q1 2025, from $13.6 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $81.0 million in Q3 2021 to a low of $90000.0 in Q2 2023.
• A 4-year average of $33.4 million and a median of $13.6 million in 2024 frame the typical range for Notes Payables.
• Peak annual rise in Notes Payables reached 10124.44% in 2024, while the deepest fall reached 10124.44% in 2024.
• Tracing CHRS's Notes Payables over 4 years: stood at $81.0 million in 2021, then tumbled by 99.89% to $90000.0 in 2023, then jumped by 15033.33% to $13.6 million in 2024, then surged by 92.57% to $26.2 million in 2025.
• Business Quant data shows CHRS's Notes Payables at $26.2 million in Q1 2025, $13.6 million in Q4 2024, and $9.2 million in Q3 2024.